Tisagenlecleucel-话题@MedSci

#Tisagenlecleucel#

1篇内容 | 1493人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2248871, encodeId=712022488e19b, content=<a href='/topic/show?id=aa081e4811f' target=_blank style='color:#2F92EE;'>#Tisagenlecleucel#</a> <a href='/topic/show?id=4e2640e283' target=_blank style='color:#2F92EE;'>#CAR-T细胞#</a> <a href='/topic/show?id=cb27123513a9' target=_blank style='color:#2F92EE;'>#喉部水肿#</a>, objectTitle=Haematologica：新研究评估了CAR-T细胞疗法tisa-cel的并发症风险, objectType=article, longId=860190, objectId=8a8486019025, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20250118/1737182934524_2185383.png, objectUrl=/article/show_article.do?id=8a8486019025, replyNumber=0, likeNumber=12, createdTime=2025-01-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1194344, encodeId=e387119434427, content=侵袭性B细胞<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a>患者接受<a href='/topic/show?id=aa081e4811f' target=_blank style='color:#2F92EE;'>#Tisagenlecleucel#</a>治疗并不优于标准疗法！看来不容易呀, objectTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, objectType=article, longId=298991, objectId=961f298991d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022217/1645056106902_1739456.jpg, objectUrl=/article/show_article.do?id=961f298991d8, replyNumber=0, likeNumber=153, createdTime=2022-02-17, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961f298991d8, moduleTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961f298991d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Tisagenlecleucel

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#Tisagenlecleucel# #CAR-T细胞# #喉部水肿#

2025-01-20发表于上海

医者仁者 (审核中...)

前往app查看评论内容

侵袭性B细胞#非霍奇金淋巴瘤#患者接受#Tisagenlecleucel#治疗并不优于标准疗法！看来不容易呀

NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较

2022-02-17

科室
- - 订阅+
  - 更多科室
工具
服务